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Abstract 
Background: Cytokine-induced-killer (CIK) cells are a promising immunotherapeutic approach for impending 
relapse following hematopoietic stem cell transplantation (HSCT). However, there is a high risk for treatment failure 
associated with severe graft versus host disease (GvHD) necessitating pharmaceutical intervention post-transplant. 
Whether immunosuppression with mycophenolate mofetil (MMF) or Ciclosporin A (CsA) influences the cytotoxic 
effect of CIK cell immunotherapy is still an open issue.
Methods: CIK cells were generated from PBMC as previously described followed by co-incubation with mycophe-
nolic acid (MPA) or CsA. Proliferation, cytotoxicity and receptor expression were investigated following short- (24 h), 
intermediate- (3 days) and long-term (7 days) MPA incubation with the intention to simulate the in vivo situation 
when CIK cells were given to a patient with relevant MPA/CsA plasma levels.
Results: Short-term MPA treatment led to unchanged proliferation capacity and barely had any effect on viability 
and cytotoxic capability in vitro. The composition of CIK cells with respect to T-, NK-like T- and NK cells remained 
stable. Intermediate MPA treatment lacked effects on NKG2D, FasL and TRAIL receptor expression, while an influence 
on proliferation and viability was detectable. Furthermore, long-term treatment significantly impaired proliferation, 
restricted viability and drastically reduced migration-relevant receptors accompanied by an alteration in the CD4/CD8 
ratio. CD3+CD56+ cells upregulated receptors relevant for CIK cell killing and migration, whereas T cells showed the 
most interference through significant reductions in receptor expression. Interestingly, CsA treatment had no signifi-
cant influence on CIK cell viability and the cytotoxic potential against K562.
Conclusions: Our data indicate that if immunosuppressant therapy is indispensable, efficacy of CIK cells is main-
tained at least short-term, although more frequent dosing might be necessary.
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Background
The transplantation of allogeneic hematopoietic stem 
cells (HSCT) is an established therapy option for the 
treatment of relapsed leukemia and other hematological 
disorders [1, 2].
For prevention and treatment of severe GvHD follow-
ing HSCT, the immunosuppressive drug mycophenolate 
mofetil (MMF; Cellcept) and Ciclosporin A (CsA) may 
be administered [3]. MMF is a prodrug which is systemi-
cally metabolized to the active metabolite mycophenolic 
acid (MPA). MPA non-competitively inhibits inosine 




*Correspondence:  melanie.bremm@kgu.de 
†Melanie Bremm and Sabine Huenecke contributed equally to this work 
1 Clinic for Pediatric and Adolescent Medicine, University Hospital, 
Theodor-Stern-Kai 7, 60596 Frankfurt/Main, Germany
Full list of author information is available at the end of the article
Page 2 of 12Bremm et al. J Transl Med  (2016) 14:264 
an important role in the de novo nucleotide synthesis. 
Thereby, MPA effectively inhibits the cell proliferation 
depending on de novo nucleotide synthesis [4–7]. CsA is 
a calcineurin inhibitor, which suppresses the activation of 
IL-2 transcription leading to a reduced immune response 
especially of T cells [8]. Patients with aGVHD  >grade I 
and/or immunosuppression are not eligible for CIK cell 
therapy. Anyhow, relevant MPA plasma levels might still 
be present at the time of CIK cell treatment due to intra- 
and inter-patient variability. In addition, CIK cells may 
cause GvHD necessitating pharmaceutical intervention, 
which among others may include the administration of 
MMF. We previously investigated the influence of MMF 
on NK cells within the scope of a clinical phase I/II study 
where patients received IL-2 stimulated NK cell immu-
notherapy to target high-risk leukemia or tumors. In 
this evaluation we observed that short-term (24 h) MPA 
incubation had no or marginal effects on the phenotype 
and only moderately reduced cytotoxic capability of IL2-
stimulated NK cells in contrast to unstimulated NK cells 
[9].
In an ongoing study we currently investigate the 
immunotherapy with cytokine induced killer (CIK) 
cells derived from peripheral blood mononuclear cells 
(PBMC) of the stem cell donor via stimulation with 
interferon (IFN)-γ, OKT-3, IL-2 and IL-15 over a period 
of 10–12  days [10–13]. CIK cells are a heterogeneous 
population primarily consisting of a minor contribution 
of CD3−CD56+ NK cells and a majority of CD3+CD56− 
T cells and CD3+CD56+ NK-like T cells [14, 15]. The 
cytotoxic activity of CIK cells against several tumor cell 
lines including leukemia, lymphoma and solid tumors 
was shown [16–19]. Among CIK cells, CD3+CD56+ NK-
like T cells, which are derived from CD3+CD56− T cells 
acquiring the CD56 molecule during expansion, showed 
the strongest proliferation and cytotoxic potential 
[14, 20, 21]. In first clinical applications we and others 
showed the safety and feasibility of CIK cell immuno-
therapy, including their relatively low propensity for 
causing GvHD even in only partially MHC-matched 
recipients [14, 22, 23]. By now, IL-15 activated CIK cells 
have been licensed as an advanced medicinal product 
for patients with high-risk leukemia and myelodysplas-
tic syndrome (ATMP § 4b Abs. 3 AMG, license number: 
PEI.A.11630.01.1) [24]. Whether immunosuppressive 
therapy influences the survival and cytotoxic effect of 
CIK cell immunotherapy remains an open issue. There-
fore, we investigated the in vitro effect of short, interme-
diate and long-term MPA incubation in therapeutically 
relevant concentrations on CIK cells which were manu-
factured over a period of 10–12  days according to our 
study protocol.
Methods
CIK cell generation and cultivation
CIK cells were generated from underweight banked 
blood of healthy donors (IRB approval 329/10) by stand-
ard ficoll separation (Biochrom AG, Berlin Germany). 
PBMC were adjusted to 3  ×  106 cells/ml and cultured 
in X-VIVO 10 media (Lonza, Verviers, Belgium) sup-
plemented with 10  % fresh frozen plasma (German 
Red Cross Blood Donor Service, Frankfurt, Germany) 
in cell culture flasks (Greiner, Nürtingen, Germany) at 
37 °C and 5 % CO2. At day 0 of CIK generation 1000 U/
ml IFN-γ (Imukin®, Boeringer Ingelheim Pharma, Ger-
many) were added, followed by 100  ng/ml anti-CD3 
mAB (OKT3, MACS GMP CD3 pure, Miltenyi Bio-
tec, Bergisch Gladbach, Germany) and 500  U/ml IL-2 
(Proleukin®S, Novartis Pharma, Nuremberg, Germany) 
24 h later (day 1). On days 4 and 8 of culture, cell den-
sity was adjusted to 1 ×  106 cells/ml and cells were re-
stimulated with 50  ng/ml IL-15 (PeproTech, Rocky Hill, 
USA) until they were harvested on day 10. CIK cells were 
split; control flasks were further supplemented only with 
50 ng/ml IL-15 every 3 days, test flasks were additionally 
spiked with a therapeutically relevant MPA concentra-
tion of 10 µM (Sigma-Aldrich, Taufkirchen, Germany) or 
of 5  µg/ml Ciclosporin A (CsA, Sandimmun®, Novartis 
Pharma GmbH, Nuremberg) after harvesting. The long 
term series received a further MPA/CsA treatment 3 days 
following harvesting.
Preparation for ex vivo investigations
For the experiments regarding cytotoxicity, surface 
receptor expression and cytokine/chemokine secre-
tion, bench scale CIK cells of healthy donors were used 
(n = 6, independent experiments). Co-incubation experi-
ments with/without MPA/CsA started after 10  days of 
cultivation. Proliferation, cytokine secretion and receptor 
expression was investigated following short- (24 h), inter-
mediate- (3 days) and long-term (7 days) MPA treatment, 
whereas cytotoxicity was investigated following short- 
and intermediate-term MPA incubation, only (Fig. 1).
Flow cytometric analyses
Flow cytometric analyses of CIK cells were performed 
on a Navios™ 10-color and a FC500 5-color flow cytom-
eter (both Beckman Coulter, Krefeld, Germany). For cell 
staining monoclonal antibodies conjugated with fluores-
cein–isothiocyanate (FITC), phycoerythrin (PE), phyco-
erythrin-Texas Red® (ECD), phycoerythrin–cyanine-5 
and 5.5 (PC-5 and PC-5.5), phycoerythrin–cyanine-7 
(PC-7), allophycocyanin (APC), APC-Alexa Fluor 700 
(APC-A700), APC-Alexa Fluor 750 (APC-A750), Pacific 
Blue™ (PB), Krome Orange (KO) were used against 
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following antigens (clones): FITC: TCRγδ (IMMU510), 
CD62L (DREG56), CD226/DNAM-1 (DX11), CD11a/
LFA-1 (HI111)2, PE: TCRαβ (BW242/412)1, CD314/
NKG2D (ON72)/(149810)4, CD173/CD95L/FAS-Ligand 
(NOK-1)2, CD183/CXCR3 (2D7)2, CD195/CCR5 (1C6)2, 
CD262/DR5/TRAIL (DJR2-4)3; ECD: CD19 (J3-119), 
CD45RO (UCHL1); PC-5.5: CD45 (J.33), CD45RO 
(UCHL1); PC-7: CD56 (N901/NKH-1); APC: CD3 
(UCHT1), CD4 (13B8.2); APC-A700: CD25 (B1.49.9); 
APC-A750: CD16 (3GB), CD3 (UCHT1); PB: CD14 
(RMO52), CD45RA (2H4); KO: CD45 (J.33), CD8 (B9.11) 
(all mouse IgG1, other than #IgG2a, *IgG2b, all antibod-
ies Beckman Coulter, except 1Miltenyi Biotec, 2BD Bio-
sciences; 3Biolegend, 4R&D Systems). For the assessment 
of cell viability 7-AAD was used. Absolute counts were 
calculated via single-platform using Flow-Count™ fluoro-
spheres (Beckman Coulter, Krefeld, Germany). All data 
were analyzed using CXP system II (Vs 2.2), Navios (Vs. 
1.2) or Kaluza (Vs. 1.2) software (Beckman Coulter, Kre-
feld, Germany).
Cytotoxicity assay
CIK cell cytotoxicity was tested against THP-1, K562 
and MOLT-4 using the non-radioactive europium 
release cytotoxicity assay as described previously [16, 
20]. To avoid the known discharge of the labeling rea-
gent BATDA, K562 were previously incubated with 
Probenecid (Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany). Target cells and CIK effector cells were co-
cultured in triplicates at effector to target (E:T) ratios 
40:1, 20:1, 10:1 and 5:1 on U-bottomed 96-well culture 
plates (Nunclon™, Thermo Fisher Scientific, Roskilde, 
Denmark). After 3 h co-incubation at 37 °C, 20 µl super-
natant was collected from each well and incubated for 
15 min (shaking, 250 rpm) with 200 µl Europium solu-
tion (PerkinElmer, Boston, USA). The fluorescence 
signal, correlating with the amount of destroyed cells, 
was then measured by a multilabel plate reader (VIC-
TOR3™ 1420 multilabel counter, PerkinElmer, Boston 
USA). Target cells without effector cells were used as 
negative control. Maximum release (positive control) 
was obtained by target cell incubation with 16  % Tri-
ton™ X-100 solution (Sigma-Aldrich Chemie, Stein-
heim, Germany). Percentage of specific cytotoxicity 
was defined as the loss of target cells in relation to the 
mono-cultured control.
Cytokine/chemokine analysis
Supernatants of expanded CIK cells after 10 days of cul-
tivation and then following 24 h, 3 and 7 days MPA incu-
bation (10  µM) with respective controls were collected 
and assayed using BioLegend LEGENDplex™ (BioLeg-
end, San Diego, USA). Data acquisition was performed 
on a Navios Flow Cytometer and analyzed with the 
LEGENDplex™ Data Analysis Software (BioLegend, San 
Diego, USA). The cell density was adjusted to 3 × 106/ml. 
The human inflammation 13-plex panel was designed for 
quantification of the cytokines/chemokines IL-1β, IFN-α, 
IFN-γ, TNF-α, MCP-1/CCL2, IL-6, IL-8, IL-10, IL-12p70, 
IL-17A, IL-18, IL-23 and IL-33. The minimum detect-
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Fig. 1 Experimental schedule of short-, intermediate- and long-term MPA/CsA incubation. CIK cells were generated by stimulation with interferon 
(IFN)-γ, OKT3, IL-2 and IL-15 over a period of 10 days. Subsequently, cells were split and either supplemented with 50 ng/ml IL-15 every 3 days (con-
trol) or additionally treated with 10 µM MPA or 5 µg/ml CsA. Proliferation, cytokine secretion and receptor expression were investigated following 
short- (24 h), intermediate- (3 days) and long-term (7 days) MPA treatment
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Statistical analysis
Statistical analysis was performed using GraphPad Prism 
6 for Windows (GraphPad Software, San Diego, USA). 
Data were compared by paired, non-parametric Fried-
mann test and differences were considered as significant 
for p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***).
Results
Influence of MPA/CsA treatment on CIK cell expansion 
and viability
CIK cells that were cultivated in the presence of MPA 
for at least 3 days showed significantly impaired prolif-
eration capacity compared to CIK cells cultivated with-
out MPA over an equal period of time (p < 0.01; Fig. 2a). 
These differences were also demonstrated for all three 
CIK cell subgroups following intermediate- and for 
T- and NK cells following long-term MPA treatment 
(p  <  0.05). Contrary, no effect of CsA treatment on 
CIK cell proliferation was observed (Additional file  1: 
Figure  S1A). Interestingly, short-term MPA treatment 
had no or only marginal effect on CIK cell viability. In 
contrast, intermediate and long-term MPA treatment 
reduced CIK cell viability by more than 30  % whereas 
CsA treatment had no significant influence on CIK cell 
viability (p < 0.01; Fig. 2b).
Cytotoxic capacity of CIK cells following MPA/CsA 
treatment
Cytotoxicity of CIK cells with and without MPA treat-
ment was investigated against the ALL cell line MOLT-4 
and the AML cell lines K562 and THP-1 whereas CsA 
treatment was investigated against the cell lines K562 
and MOLT-4 (Fig.  3). The cytotoxic effect of MPA 
treated CIK cells against K562 cells was influenced 
by MPA exposure, though only in the 40:1 ratio a sig-
nificant reduction of the killing capacity was obtained 
(p < 0.05, Fig. 3a). In contrast, no differences in the lytic 
activity of CsA incubated and wildtype CIK cells were 
observed against K562 (Fig.  3b). Regarding MOLT-4 
killing, short-term MPA treatment did not affect tar-
get cell lysis compared to untreated control CIK cells 
(Fig.  3c). However we observed a reduced lysis of 
MOLT-4 cells by CIK cells treated with MPA for 3 days 
(intermediate term) in the E:T ratios 10:1, 20:1 and 
40:1 (p  <  0.05). CsA-treated and wildtype CIK cells 
showed comparable results in MOLT-4 killing (data 
not shown). Interestingly, no difference in the lysis of 
THP-1 target cells of CIK cells with and without MPA 
incubation were determined (Fig. 3d). Long-term MPA 
treatment resulted in strong reduction of absolute CIK 
cell number. Therefore, cytotoxicity testing could not be 
investigated.
Changes in receptor expression and cytokine secretion 
as consequence of MPA treatment
Although absolute numbers of T cells declined, we 
observed an alteration in the CD4/CD8 ratio following 
MPA treatment of CIK cells. Interestingly, the percent-
age of CD8+ cells decreased, while the percentage of 
CD4+ cells increased (Fig.  4a). Comparing the propor-
tion of CD8+ cells following long-term and without MPA 
treatment revealed a significant decrease in CD8+ cells 
(p  <  0.05). In accordance, intermediate and long-term 
MPA incubation were associated with a statistically sig-
nificant higher percentage of CD4+ cells (p  <  0.05 and 
p < 0.01).
The characterization of NKG2D receptor on CD4+ and 
CD8+ cells showed stable expression upon short- and 
intermediate-term MPA treatment. Only following long-
term MPA incubation, downregulation of NKG2D was 
observed (p < 0.05, Fig. 4b). Further analysis also revealed 
stable expression of NKG2D on CIK cell subpopulations 
(T, NK and NK-like T cells) during short- and interme-
diate-term MPA incubation, whereas reduced NKG2D 
receptor expression was observed following long-term 
MPA exposure (T and NK cells: p < 0.05; NK-like T cells: 
p < 0.01, Fig. 4c).
Regarding CD25, we observed loss of expression when 
CIK cells were cultivated for longer than the usual cul-
ture period of 10 days. However, this reduction in CD25 
expression was enhanced following MPA incubation, 
showing the most pronounced differences for NK-like 
T cells after intermediate- and long-term MPA treat-
ment (p < 0.01) (Fig. 4d). Interestingly, we also observed 
a reduction in CD25 expression implicated by CsA treat-
ment. T and NK-like T cells showed a significant reduc-
tion of CD25 expression following three (p  <  0.01) and 
7 days (p < 0.05) of CsA treatment whereas no significant 
alteration of CD25 expression on NK cells was observed 
(Additional file 1: Figure S1B). Furthermore, no changes 
in NKG2D expression in CsA treated CIK cells were 
examined (data not shown).
FasL, TRAIL and DNAM, which are mainly involved 
in target cell killing, were influenced by MPA to a minor 
extent. Following long-term MPA treatment we deter-
mined a decrease in FasL and TRAIL expression on T 
cells and an increase of DNAM expression on NK-like T 
cells (p  <  0.05, Fig.  5). In contrast, CD11a, CXCR3 and 
CCR5, which are primarily involved in CIK cell migra-
tion, were more susceptible to MPA exposure. Interest-
ingly, the percentage of T cells expressing CD11a was 
reduced, but increased on NK-like T and NK cells follow-
ing intermediate- and long-term treatment (p < 0.05 and 
p < 0.01). Furthermore, T cells showed reduced CXCR3 
expression following long-term, whereas NK-like T cells 
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Fig. 2 Ex vivo CIK cell expansion upon MPA- and viability with and without MPA/CsA treatment. a Proliferation capacity of CIK cells in the presence 
and absence of MPA for the indicated time-points. Intermediate- (3 days) and long-term (7 days) MPA treatment resulted in an impaired prolifera-
tion capacity of CIK cells (p < 0.01), whereas short-term (24 h) MPA exposure had only marginal effect on CIK cell expansion. The most prominent 
reduction in expansion was seen for NK-like T cells following long-term MPA exposure (p < 0.01). b Short-term MPA incubation had no or only mar-
ginal effect on CIK cell viability. In contrast, intermediate- and long-term MPA treatment resulted in a significantly reduced CIK cell viability (p < 0.01; 
n = 6 independent experiments). CsA treatment had no effect on CIK cell viability (n = 4 independent experiments)
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up-regulated CCR5 upon intermediate- and long-term 
treatment with MPA (p < 0.05).
We also analyzed a panel of cytokines, i.e. IL-8, IFN-γ, 
MCP-1/CCL2, IL-6, IL-1β and TNFα, following short-, 
intermediate- and long-term MPA exposure or control 
incubation. Similar to CD25 expression, cytokine release 
was attenuated by extended cultivation. In other words, 
impaired functionality in terms of cytokine release was 
MOLT- 4
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Fig. 3 Influence of MPA/CsA exposure on CIK cell cytotoxicity. We investigated a non-radioactive europium release cytotoxicity assay to test the 
cytotoxicity of MPA treated CIK cells against the ALL cell line MOLT-4 and the AML cell lines K562 and THP-1 and the lytic activity of CsA treated CIK 
cells against K562. a Killing of K562 was influenced only by intermediate-term MPA treatment in the E:T ratio 40:1 with a median killing rate of 62.4 % 
(SD: 23.3) without and 48.2 % (SD: 24.1) with MPA treatment. b CsA treatment of CIK cells did not influence their cytotoxicity against K562 cells. c 
CIK cell mediated MOLT-4 cell lysis was not significantly influenced by short-term (24 h) MPA treatment, whereas intermediate-term (3 days) MPA 
incubation resulted in reduced killing rates in E:T ratios 10:1, 20:1 and 40:1 (p < 0.05). CIK cell mediated killing was in mean 25.5 % (SD: 9.3), 44.6 % 
(SD: 5.5), 68.3 % (SD: 10.3) following 3 days without treatment compared to 12.4 % (SD: 13.7), 20.8 % (SD: 17.7), 36.8 % (SD: 27.1) with intermediate-
term MPA treatment in E:T ratios 10:1, 20:1 and 40:1, respectively. d In contrast to MOLT-4 and K562, the killing efficiency of CIK cells against THP-1 
cells was obviously reduced. There was no difference in the lysis of THP-1 target cells of CIK cells with and without MPA incubation. n = 4 independ-
ent experiments, respectively
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not primarily influenced by MPA, but rather through the 
prolonged activation period. The only cytokine signifi-
cantly reduced after long-term MPA compared to control 
was TNFα (Additional file 2: Figure S2).
Discussion
Immunotherapeutic strategies are of increasing interest 
in the therapy of emerging minimal residual disease or 
incomplete donor chimerism following HSCT. We and 
others have previously shown that IL-15 stimulated CIK 
cells are a promising immunotherapeutic approach for 
the treatment of patients with impending relapse follow-
ing allogeneic SCT for acute leukemia or myelodysplastic 
syndrome [13, 19, 22, 25, 26].
CIK cells consist of a heterogeneous population of 
CD3+ T cells, CD3+CD56+ NK-like T cells and a minor 
part of CD3−CD56+ NK cells [14]. Thereby, CIK cells are 
able to kill tumor cells via diverse TCR specificities and 
in a non-MHC-restricted manner [27]. Different studies 
indicated an anti-tumor effect of CIK cells against various 
tumor cells mediated by the receptors or ligands NKG2D, 
TRAIL, DNAM and FasL [16, 28, 29]. In first clinical 
applications, CIK cell infusions were well tolerated and 
showed low incidence of GvHD even in the haplo-identi-
cal setting, which was postulated to be mainly due to less 
trafficking of CIK cells to GvHD sites [30], and due to the 
lack of corresponding ligands or receptors on normal tis-
sues and hematopoietic progenitors.
Beside antileukemic efficacy, CIK cell treatment may 
be associated with increased risk for developing severe 
GvHD, especially when being applied in the haploidenti-
cal setting and in the early post-transplant period requir-
ing immunosuppressive treatment. Furthermore, even 
if immunosuppression like MMF is stopped in patients 
at risk for relapse after HSCT, relevant MPA plasma 
levels might be present due to intra- and inter-patient 
variability [31]. Therefore, the influence of immuno-
suppressive treatment, on the efficacy of cellular inter-
ventions needs to be further investigated. Hence, we 
analyzed the phenotype, survival and cytotoxic capacity 
of CIK cells during short-, intermediate- and long-term 
presence of MMF in vitro.
Within this study, we observed that CIK cell cytotox-
icity was maintained during short-term MPA exposure, 
while intermediate- and long-term MPA treatment atten-
uated proliferation capacity, viability and cytotoxicity. 
Comparable results were obtained by Brehm et al. [9] for 
NK cells within the scope of a clinical phase I/II study in 
short- and long-term MPA treatment. In this study, NK 
cells were co-incubated with MPA just at the beginning 
of cytokine activation. In our new approach, we first gen-
erated the immunotherapeutic cells and then exposed 
them to MPA. Eissens et al. [32] and Ohata et al. [33] also 
described that MPA clearly impeded the outgrowth and 
the cytotoxic effect of NK cells treated with MPA. Unfor-
tunately, a short-term MPA treatment was not investi-
gated in these two studies. These results are contradicting 
Shapira et  al. [34] who suggested that MMF does not 
impair GvL-effect or reduce LAK cell activity in mice. 
However, this might be explained by differing study pro-
tocols. Shapira et al. treated mice with MMF for a period 
of 8 days and afterwards generated autologous LAK cells 
without further addition of MMF. In contrast, we gener-
ated CIK cells according to our study protocol for 10 days 
and started MPA treatment after harvesting with the 
intention to simulate in vitro the situation when CIK cells 
were given to a patient who has therapeutic MPA plasma 
levels.
Most importantly, none or at most a marginal effect 
on CIK cell proliferation was seen following short-term 
MPA incubation. Therefore, our findings are promising, 
that in case of indispensable immunosuppression post 
(See figure on next page.) 
Fig. 5 Influence of MPA exposure on receptors involved in CIK cell mediated killing and cell migration. FasL, TRAIL, DNAM, CD11a, CXCR3 and CCR5 
were analyzed following short- (24 h), intermediate- (3 days) and long-term (7 days) MPA treatment and all receptors were compared to their indi-
vidual controls (only 24 h control is displayed). a–c Analyzing receptors involved in CIK cell mediated killing, we observed a stable expression of FasL, 
TRAIL and DNAM upon short- and intermediate-term MPA treatment. A reduced expression of FasL and TRAIL on T cells and an increased expres-
sion of DNAM following long-term MPA exposure was determined (p < 0.05). d–f With regard to CIK cell migration, no alteration in the expression 
of CD11a, CXCR3 and CCR5 upon short-term MPA exposure was observed. CD11a was downregulated on T cells and upregulated on NK-like T and 
NK cells following intermediate- and long-term MPA treatment (p < 0.05 and p < 0.01). CXCR3 was downregulated on T cells upon long-term MPA 
incubation (p < 0.05), whereas CCR5 was expressed to a higher extend on NK-like T cells. n = 5 independent experiments
(See figure on previous page.) 
Fig. 4 Changes in CIK cell composition induced by MPA treatment. The influence of MPA treatment on receptor expression was analyzed for 
CD4, CD8, NKG2D and CD25. a The percentage of CD8+ cells decreased, whereas the proportion of CD4+ cells increased. b, c NKG2D was steadily 
expressed during short- (24 h) and intermediate-term (3 days) MPA treatment, only showing a reduction after long-term (7 days) MPA exposure. d 
CD25 expression clearly declined on T cells following long-term MPA exposure (p < 0.05) and on NK cells following intermediate- and long-term 
MPA treatment (p < 0.05). The most significant reduction in CD25 expression was shown for NK-like T cells after intermediate- and long-term MPA 
exposure. n = 6 independent experiments
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HSCT, the therapy with IL-15 stimulated CIK cells will 
have at least short-term efficacy. We observed no signifi-
cant differences of killing relevant receptor expressions 
of the NKG2D, TRAIL, DNAM and FasL receptors upon 
short- and intermediate-term MPA exposure. However, 
we revealed that T cells and NK-like T cells reacted dif-
ferently upon MPA exposure. CD3+CD56+ NK-like T 
cells upregulated receptors relevant for CIK cell killing 
and migration, whereas CD3+ T cells downregulated 
these receptors. CsA treatment resulted in a non-signif-
icant reduction of proliferation and cytotoxicity, only. 
These results are comparable to Mehta et al. [35] describ-
ing that CsA inhibited anti-CD3-mediated degranula-
tion, but did not affect cytotoxicity of CIK cells against 
tumor targets. Regarding cytokine/chemokine secretion, 
we observed no significant differences between CIK cells 
with and without MPA treatment expect for a significant 
reduction in TNFα secretion. These results are in accord-
ance with Liu et al. [36] who published promising results 
combining CIK cell therapy with CsA treatment also 
describing the secretion of various cytokines including 
IL-2 and IL-8. In contrast, Brehm et al. [9] and Nagy et al. 
[37] reported a significant reduction in the secretion of 
IFNγ, IL-6 and other cytokines by NK cells upon MPA 
treatment, but here immune cells were co-incubated with 
MPA already during cultivation time.
Following infusion, CIK cells are described to accumu-
late and persist in tumor sites, resulting in tumor eradica-
tion [30]. Wang et  al. [38] analyzed CIK cell homing of 
18F-FDG labeled CIK cells in leukemia patients by PET/
CT tracking. They figured out, that 1 h following CIK cell 
infusion, the majority of CIK cells accumulated in the 
lungs, followed by a migration into brain, heart, liver and 
spleen at the time points 4 and 8  h post CIK cell ther-
apy. Furthermore, tendencies of CIK cell homing into the 
bone marrow were shown. In the study described herein, 
we observed that short-term MPA incubation had no 
pronounced effect on proliferation, viability, cytotoxicity 
and CIK cell composition. Linking this information to the 
homing parameters analyzed by Wang et  al., we might 
speculate that during a window of 24 h where hardly any 
influence of MPA on the CIK cells was seen, CIK cells 
might migrate to tumor sites and achieve a cytotoxic 
effect.
Conclusions
In conclusion, already generated IL-15 CIK cells that were 
co-incubated with MPA for at least 3 days showed signifi-
cantly impaired proliferation capacity, restricted viability, 
alterations in receptor expression and a reduction in their 
cytotoxic capability compared to CIK cells that were cul-
tivated without MPA. Interestingly, CsA treatment had 
no significant influence on CIK cell viability and the cyto-
toxic potential against K562. However, a short-term MPA 
incubation had only marginal or reduced effect on CIK 
cells. The favored strategy is to avoid immunosuppres-
sion in patients who received CIK cell immuno-therapy. 
However, our findings showed, that even in patients with 
immunosuppression e.g. for treatment of GvHD, CIK cell 
treatment may have at least short-term efficacy.
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